» Articles » PMID: 9711875

Detection of Known and New Mutations in the Thiopurine S-methyltransferase Gene by Single-strand Conformation Polymorphism Analysis

Overview
Journal Hum Mutat
Specialty Genetics
Date 1998 Aug 26
PMID 9711875
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

To detect mutations in the thiopurine S-methyltransferase gene (TPMT), we have developed a strategy based on single-strand conformation polymorphism (SSCP) analysis of the gene amplified by polymerase chain reaction (PCR). The sensitivity of the method was first evaluated by analyzing DNA samples from five individuals, including two high methylators (HMs), two intermediate methylators (IMs), and one deficient methylator (DM). TPMT alleles and mutations in each of these individuals had previously been characterized by conventional PCR-based assays and direct sequencing analysis. All mutations were associated with particular shifts in the electrophoretic mobility of DNA fragments, allowing their identification. We further tested the efficiency of the strategy to detect new TPMT mutations. For this purpose, additional DNAs from 15 IMs and 15 HMs were submitted to PCR-SSCP analysis. A total of 7 alleles were characterized, including two new alleles. The first one, termed TPMT*1A, harbors a single mutation C-->T at nucleotide -178 in exon 1 and was detected in a HM subject. The second one, termed TPMT*7, was characterized by a T-->G transversion at nucleotide 681 in exon 10. This allele should be a nonfunctional allele of the TPMT gene since it was observed in combination with a wild-type allele in an intermediate methylator. We conclude that the PCR-SSCP strategy we developed could be advantageously used to fully characterize the extent of allelic variation at the TPMT gene locus in populations and thus to improve our understanding of the genetic polymorphism of TPMT activity, which has considerable consequences for the toxicity and efficacy of therapeutically important and widely used drugs.

Citing Articles

A bioinformatics approach to the identification of novel deleterious mutations of human TPMT through validated screening and molecular dynamics.

Saxena S, Murthy T, Chandrashekhar C, Patil L, Aditya A, Shukla R Sci Rep. 2022; 12(1):18872.

PMID: 36344599 PMC: 9640560. DOI: 10.1038/s41598-022-23488-z.


and testing for thiopurine therapy: A major tertiary hospital experience and lessons learned.

Goh L, Lim C, Leong K, Ong K Front Pharmacol. 2022; 13:837164.

PMID: 36210828 PMC: 9537458. DOI: 10.3389/fphar.2022.837164.


Role of Genetic Polymorphisms in Drug-Metabolizing Enzyme-Mediated Toxicity and Pharmacokinetic Resistance to Anti-Cancer Agents: A Review on the Pharmacogenomics Aspect.

Narendra G, Choudhary S, Raju B, Verma H, Silakari O Clin Pharmacokinet. 2022; 61(11):1495-1517.

PMID: 36180817 DOI: 10.1007/s40262-022-01174-7.


Insights into S-adenosyl-l-methionine (SAM)-dependent methyltransferase related diseases and genetic polymorphisms.

Li J, Sun C, Cai W, Li J, Rosen B, Chen J Mutat Res Rev Mutat Res. 2021; 788:108396.

PMID: 34893161 PMC: 8847900. DOI: 10.1016/j.mrrev.2021.108396.


In Vitro Protein Stability of Two Naturally Occurring Thiopurine -Methyltransferase Variants: Biophysical Characterization of TPMT*6 and TPMT*8.

Wennerstrand P, Blissing A, Martensson L ACS Omega. 2018; 2(8):4991-4999.

PMID: 30023734 PMC: 6044926. DOI: 10.1021/acsomega.7b00801.